Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Role of a Contactin multi-molecular complex secreted by oligodendrocytes in nodal protein clustering in the CNS.

Dubessy AL, Mazuir E, Rappeneau Q, Ou S, Abi Ghanem C, Piquand K, Aigrot MS, Thétiot M, Desmazières A, Chan E, Fitzgibbon M, Fleming M, Krauss R, Zalc B, Ranscht B, Lubetzki C, Sol-Foulon N.

Glia. 2019 Jul 22. doi: 10.1002/glia.23681. [Epub ahead of print]

PMID:
31328333
2.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

PMID:
31300547
3.

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.

Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, Geurts JJG, Paul F, Reich DS, Toosy AT, Traboulsee A, Wattjes MP, Yousry TA, Gass A, Lubetzki C, Weinshenker BG, Rocca MA.

Brain. 2019 Jun 17. pii: awz144. doi: 10.1093/brain/awz144. [Epub ahead of print]

4.

The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study.

Chazal T, Costopoulos M, Maillart E, Fleury C, Psimaras D, Legendre P, Pineton de Chambrun M, Haroche J, Lubetzki C, Amoura Z, Legarff-Tavernier M, Cohen Aubart F.

Eur J Neurol. 2019 Apr 25. doi: 10.1111/ene.13975. [Epub ahead of print]

PMID:
31021023
5.

Melanoma during fingolimod treatment for multiple sclerosis.

Velter C, Thomas M, Cavalcanti A, Bastien M, Chochon F, Lubetzki C, Routier E, Robert C.

Eur J Cancer. 2019 May;113:75-77. doi: 10.1016/j.ejca.2019.03.011. Epub 2019 Apr 12. No abstract available.

PMID:
30986706
6.

Preparation and Immunostaining of Myelinating Organotypic Cerebellar Slice Cultures.

Thetiot M, Ronzano R, Aigrot MS, Lubetzki C, Desmazières A.

J Vis Exp. 2019 Mar 20;(145). doi: 10.3791/59163.

PMID:
30958468
7.

Impact of an adaptive program for cognitive and emotional deficits (ADACOG program) in multiple sclerosis patients with cognitive impairments.

Pineau F, Socha J, Corvol JC, Louapre C, Assouad R, Maillart E, Lubetzki C, Papeix C.

Rev Neurol (Paris). 2019 May;175(5):305-312. doi: 10.1016/j.neurol.2018.08.008. Epub 2019 Mar 23.

PMID:
30910222
8.

Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.

Lebrun-Frenay C, Moulignier A, Pierrot-Deseilligny C, Benrabah R, Moreau T, Lubetzki C, Monchecourt F; Copaxone Observatory.

J Neurol. 2019 Apr;266(4):888-901. doi: 10.1007/s00415-019-09211-5. Epub 2019 Feb 7.

9.

False hepatitis B and C viral serologies in patients with multiple sclerosis receiving high-dose biotin.

Pourcher V, Todesco E, Dubois C, Pallier C, Lubetzki C, Louapre C, Papeix C, Maillart E.

Mult Scler. 2018 Dec 11:1352458518818294. doi: 10.1177/1352458518818294. [Epub ahead of print] No abstract available.

PMID:
30526282
10.

150 years since Charcot's lectures on multiple sclerosis.

Lubetzki C.

Lancet Neurol. 2018 Dec;17(12):1041. doi: 10.1016/S1474-4422(18)30410-1. Epub 2018 Nov 13. No abstract available.

PMID:
30507389
11.

Cerebral folate deficiency in adults: A heterogeneous potentially treatable condition.

Masingue M, Benoist JF, Roze E, Moussa F, Sedel F, Lubetzki C, Nadjar Y.

J Neurol Sci. 2019 Jan 15;396:112-118. doi: 10.1016/j.jns.2018.11.014. Epub 2018 Nov 10.

PMID:
30448717
12.

Making a 'JUMP' from paediatric to adult healthcare: A transitional program for young adults with chronic neurological disease.

Mc Govern EM, Maillart E, Bourgninaud M, Manzato E, Guillonnet C, Mochel F, Bourmaleau J, Lubetzki C, Baulac M, Roze E.

J Neurol Sci. 2018 Dec 15;395:77-83. doi: 10.1016/j.jns.2018.09.030. Epub 2018 Sep 26.

PMID:
30296734
13.

Efficacy of rituximab in refractory RRMS.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B.

Mult Scler. 2019 May;25(6):828-836. doi: 10.1177/1352458518772748. Epub 2018 May 3.

PMID:
29722639
14.

Steps towards Collective Sustainability in Biomedical Research.

Salvetti M, Lubetzki C, Kapoor R, Ristori G, Costa E, Battaglia MA, Andreaus M, Abbracchio MP, Matarese G, Zaratin P.

Trends Mol Med. 2018 May;24(5):429-432. doi: 10.1016/j.molmed.2018.03.001. Epub 2018 Mar 24.

PMID:
29588144
15.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

16.

Early relapse after RTX initiation in a patient with NMO/MS overlap syndrome: How long to conclude to a failure treatment?

Maillart E, Lippi A, Lubetzki C, Louapre C, Papeix C.

Mult Scler Relat Disord. 2018 Feb;20:220-222. doi: 10.1016/j.msard.2018.02.004. Epub 2018 Feb 6.

PMID:
29433095
17.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
18.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
19.

Multiple sclerosis and aging.

Louapre C, Papeix C, Lubetzki C, Maillart E.

Geriatr Psychol Neuropsychiatr Vieil. 2017 Dec 1;15(4):402-408. doi: 10.1684/pnv.2017.0685. Review.

PMID:
29081400
20.

Transient hypothyroidism favors oligodendrocyte generation providing functional remyelination in the adult mouse brain.

Remaud S, Ortiz FC, Perret-Jeanneret M, Aigrot MS, Gothié JD, Fekete C, Kvárta-Papp Z, Gereben B, Langui D, Lubetzki C, Angulo MC, Zalc B, Demeneix B.

Elife. 2017 Sep 6;6. pii: e29996. doi: 10.7554/eLife.29996.

21.

The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination.

Mannioui A, Vauzanges Q, Fini JB, Henriet E, Sekizar S, Azoyan L, Thomas JL, Pasquier DD, Giovannangeli C, Demeneix B, Lubetzki C, Zalc B.

Mult Scler. 2018 Oct;24(11):1421-1432. doi: 10.1177/1352458517721355. Epub 2017 Jul 28.

PMID:
28752787
22.

Fatigue evaluation in fingolimod treated patients: An observational study.

Masingue M, Debs R, Maillart E, Delvaux V, Lubetzki C, Vidal JS, Papeix C.

Mult Scler Relat Disord. 2017 May;14:8-11. doi: 10.1016/j.msard.2017.03.006. Epub 2017 Mar 14.

PMID:
28619437
23.

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome.

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, Lubetzki C, Papeix C.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

24.

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center.

Roux T, Maillart E, Vidal JS, Tezenas du Montcel S, Lubetzki C, Papeix C.

Front Neurol. 2017 May 5;8:183. doi: 10.3389/fneur.2017.00183. eCollection 2017.

25.

Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy.

Bodini B, Branzoli F, Poirion E, García-Lorenzo D, Didier M, Maillart E, Socha J, Bera G, Lubetzki C, Ronen I, Lehericy S, Stankoff B.

Mult Scler. 2018 Mar;24(3):313-321. doi: 10.1177/1352458517698249. Epub 2017 Apr 10.

PMID:
28394203
26.

Imaging markers of multiple sclerosis prognosis.

Louapre C, Bodini B, Lubetzki C, Freeman L, Stankoff B.

Curr Opin Neurol. 2017 Jun;30(3):231-236. doi: 10.1097/WCO.0000000000000456. Review.

PMID:
28362719
27.

Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?

Boudot de la Motte M, Louapre C, Bertrand A, Reach P, Lubetzki C, Papeix C, Maillart E.

Mult Scler. 2017 Apr;23(4):614-616. doi: 10.1177/1352458516682858. Epub 2016 Dec 14.

PMID:
28273764
28.

Fast multiple sclerosis progression in North Africans: Both genetics and environment matter.

Sidhom Y, Maillart E, Tezenas du Montcel S, Kacem I, Lubetzki C, Gouider R, Papeix C.

Neurology. 2017 Mar 28;88(13):1218-1225. doi: 10.1212/WNL.0000000000003762. Epub 2017 Feb 24.

PMID:
28235811
29.

Involvement of peripheral III nerve in multiple sclerosis patient: Report of a new case and discussion of the underlying mechanism.

Shor N, Amador MD, Dormont D, Lubetzki C, Bertrand A.

Mult Scler. 2017 Apr;23(5):748-750. doi: 10.1177/1352458516687401. Epub 2017 Feb 10.

PMID:
28185472
30.

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.

Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, Uhry Z, Van Ganse E, Castot A, Clanet M, Lubetzki C, Confavreux C; TYSEDMUS and OFSEP Group.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297. eCollection 2016 Dec.

31.

Favorable outcome of a pregnancy after fampridine exposition during the first month.

Maillart E, Gout O, Lubetzki C, Carpentier B, Nizard J.

J Neurol Sci. 2016 Nov 15;370:158. doi: 10.1016/j.jns.2016.09.033. Epub 2016 Sep 24. No abstract available.

PMID:
27772749
32.

Extensive and severe CNS demyelination associated with golimumab therapy.

Maillart E, Papeix C, Mellerio C, Bertrand A, Lubetzki C, Louapre C.

J Neurol. 2016 Sep;263(9):1869-71. doi: 10.1007/s00415-016-8238-5. Epub 2016 Jul 25. No abstract available.

PMID:
27456211
33.

Integrated multidisciplinary clinics should be the gold standard in managing progressive MS - NO.

Papeix C, Lubetzki C.

Mult Scler. 2016 Aug;22(9):1128-30. doi: 10.1177/1352458516643397. Epub 2016 May 25. No abstract available.

PMID:
27225675
34.

Functional Characterization of DNA Methylation in the Oligodendrocyte Lineage.

Moyon S, Huynh JL, Dutta D, Zhang F, Ma D, Yoo S, Lawrence R, Wegner M, John GR, Emery B, Lubetzki C, Franklin RJM, Fan G, Zhu J, Dupree JL, Casaccia P.

Cell Rep. 2016 Apr 26;15(4):748-760. doi: 10.1016/j.celrep.2016.03.060. Epub 2016 Apr 14.

35.

Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact.

Clark KC, Josephson A, Benusa SD, Hartley RK, Baer M, Thummala S, Joslyn M, Sword BA, Elford H, Oh U, Dilsizoglu-Senol A, Lubetzki C, Davenne M, DeVries GH, Dupree JL.

Glia. 2016 Jul;64(7):1190-209. doi: 10.1002/glia.22991. Epub 2016 Apr 21.

PMID:
27100937
36.

Recent achievements in stem cell-mediated myelin repair.

Jadasz JJ, Lubetzki C, Zalc B, Stankoff B, Hartung HP, Küry P.

Curr Opin Neurol. 2016 Jun;29(3):205-12. doi: 10.1097/WCO.0000000000000323. Review.

PMID:
27035898
37.

Repair strategies for multiple sclerosis: challenges, achievements and perspectives.

Stankoff B, Jadasz JJ, Hartung HP, Küry P, Zalc B, Lubetzki C.

Curr Opin Neurol. 2016 Jun;29(3):286-92. doi: 10.1097/WCO.0000000000000325. Review.

PMID:
27035897
38.

Dynamic Imaging of Individual Remyelination Profiles in Multiple Sclerosis.

Bodini B, Veronese M, García-Lorenzo D, Battaglini M, Poirion E, Chardain A, Freeman L, Louapre C, Tchikviladze M, Papeix C, Dollé F, Zalc B, Lubetzki C, Bottlaender M, Turkheimer F, Stankoff B.

Ann Neurol. 2016 May;79(5):726-738. doi: 10.1002/ana.24620.

39.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators.

Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Erratum in: Lancet. 2017 Jan 21;389(10066):254.

PMID:
26827074
40.

Dramatic worsening of adult-onset X-linked adrenoleukodystrophy after head trauma.

Bouquet F, Dehais C, Sanson M, Lubetzki C, Louapre C.

Neurology. 2015 Dec 1;85(22):1991-3. doi: 10.1212/WNL.0000000000002173. Epub 2015 Nov 4. No abstract available.

PMID:
26537054
41.

Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes.

Louapre C, Lubetzki C.

Mult Scler. 2015 Nov;21(13):1626-8. doi: 10.1177/1352458515587598. No abstract available.

PMID:
26515289
42.

Mechanisms of sodium channel clustering and its influence on axonal impulse conduction.

Freeman SA, Desmazières A, Fricker D, Lubetzki C, Sol-Foulon N.

Cell Mol Life Sci. 2016 Feb;73(4):723-35. doi: 10.1007/s00018-015-2081-1. Epub 2015 Oct 29. Review.

43.

Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.

Debs R, Maillart E, Fahed R, Papeix C, Duyckaerts C, Stadelmann C, Galanaud D, Lubetzki C.

Neurology. 2015 Nov 3;85(18):1630-2. doi: 10.1212/WNL.0000000000002084. Epub 2015 Oct 9. No abstract available.

PMID:
26453649
44.

Evaluation of an integrated multidisciplinary approach in multiple sclerosis care: A prospective, randomized, controlled study.

Papeix C, Gambotti L, Assouad R, Ewenczyck C, Tanguy ML, Pineau F, Houis MC, Mazevet D, Maillart E, Lubetzki C.

Mult Scler J Exp Transl Clin. 2015 Sep 28;1:2055217315608864. doi: 10.1177/2055217315608864. eCollection 2015 Jan-Dec.

45.

The neuronal component of gray matter damage in multiple sclerosis: A [(11) C]flumazenil positron emission tomography study.

Freeman L, Garcia-Lorenzo D, Bottin L, Leroy C, Louapre C, Bodini B, Papeix C, Assouad R, Granger B, Tourbah A, Dollé F, Lubetzki C, Bottlaender M, Stankoff B.

Ann Neurol. 2015 Oct;78(4):554-67. doi: 10.1002/ana.24468. Epub 2015 Aug 21.

PMID:
26292991
46.

Patterns of Objective and Subjective Burden of Informal Caregivers in Multiple Sclerosis.

Bayen E, Papeix C, Pradat-Diehl P, Lubetzki C, Joël ME.

Behav Neurol. 2015;2015:648415. doi: 10.1155/2015/648415. Epub 2015 May 20.

47.

Fecundity in women with multiple sclerosis: an observational mono-centric study.

Roux T, Courtillot C, Debs R, Touraine P, Lubetzki C, Papeix C.

J Neurol. 2015;262(4):957-60. doi: 10.1007/s00415-015-7663-1. Epub 2015 Feb 12.

PMID:
25673128
48.

Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration.

Moyon S, Dubessy AL, Aigrot MS, Trotter M, Huang JK, Dauphinot L, Potier MC, Kerninon C, Melik Parsadaniantz S, Franklin RJ, Lubetzki C.

J Neurosci. 2015 Jan 7;35(1):4-20. doi: 10.1523/JNEUROSCI.0849-14.2015.

49.

Acceleration of conduction velocity linked to clustering of nodal components precedes myelination.

Freeman SA, Desmazières A, Simonnet J, Gatta M, Pfeiffer F, Aigrot MS, Rappeneau Q, Guerreiro S, Michel PP, Yanagawa Y, Barbin G, Brophy PJ, Fricker D, Lubetzki C, Sol-Foulon N.

Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):E321-8. doi: 10.1073/pnas.1419099112. Epub 2015 Jan 5.

50.

[Editorial].

Antoine JC, Liblau R, Lubetzki C.

Rev Neurol (Paris). 2014 Oct;170(10):559-60. doi: 10.1016/j.neurol.2014.09.001. French. No abstract available.

PMID:
25280980

Supplemental Content

Loading ...
Support Center